Stocks
AtriCure Financial Statements (ATRC) |
||||||||||
| AtriCuresmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.02.2021 | 17.02.2022 | 31.12.2022 | 22.02.2023 | 16.02.2024 | 30.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 206.5 | 274.3 | 330.4 | 330.4 | 399.2 | 447.6 | |||
| Operating Income, bln rub | -44.2 | -47.3 | -42.7 | -42.7 | -26.7 | -34.2 | ||||
| EBITDA, bln rub | ? | -33.6 | -36.9 | -46.2 | -29.5 | -8.11 | -12.9 | |||
| Net profit, bln rub | ? | -48.2 | 50.2 | -46.5 | -46.5 | -30.4 | -38.9 | |||
| OCF, bln rub | ? | -19.9 | -13.8 | -22.1 | 4.48 | 10.4 | ||||
| CAPEX, bln rub | ? | 5.26 | 9.75 | 16.9 | 42.0 | 11.6 | ||||
| FCF, bln rub | ? | -25.1 | -23.5 | -39.0 | -37.5 | -1.15 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 193.5 | 253.2 | 288.6 | 288.6 | 327.1 | 366.6 | ||||
| Cost of production, bln rub | 57.2 | 68.5 | 84.4 | 84.4 | 98.9 | 115.1 | ||||
| R&D, bln rub | 43.1 | 48.5 | 57.3 | 57.3 | 73.9 | 81.3 | ||||
| Interest expenses, bln rub | 4.89 | 4.92 | 0.000 | 4.99 | 6.93 | 6.75 | ||||
| Assets, bln rub | 714.5 | 615.3 | 585.4 | 585.4 | 613.9 | 615.1 | ||||
| Net Assets, bln rub | ? | 412.4 | 483.8 | 456.8 | 456.8 | 466.2 | 465.0 | |||
| Debt, bln rub | 74.0 | 75.6 | 69.1 | 69.1 | 74.5 | 77.1 | ||||
| Cash, bln rub | 244.2 | 119.1 | 121.1 | 121.1 | 137.3 | 130.3 | ||||
| Net debt, bln rub | -170.2 | -43.4 | -52.0 | -52.0 | -62.8 | -53.2 | ||||
| Ordinary share price, rub | 55.7 | 69.5 | 44.4 | 44.4 | 35.7 | 33.5 | ||||
| Number of ordinary shares, mln | 42.1 | 45.1 | 42.1 | 45.7 | 46.3 | 47.1 | ||||
| Market cap, bln rub | 2 345 | 3 133 | 1 870 | 2 030 | 1 653 | 1 578 | ||||
| EV, bln rub | ? | 2 175 | 3 090 | 1 817 | 1 978 | 1 590 | 1 525 | |||
| Book value, bln rub | 49 | 206 | 457 | 183 | 167 | 172 | ||||
| EPS, rub | ? | -1.14 | 1.11 | -1.10 | -1.02 | -0.66 | -0.83 | |||
| FCF/share, rub | -0.60 | -0.52 | 0.00 | -0.85 | -0.81 | -0.02 | ||||
| BV/share, rub | 1.17 | 4.57 | 10.8 | 3.99 | 3.61 | 3.65 | ||||
| EBITDA margin, % | ? | -16.3% | -13.4% | -14.0% | -8.93% | -2.03% | -2.89% | |||
| Net margin, % | ? | -23.3% | 18.3% | -14.1% | -14.1% | -7.62% | -8.70% | |||
| FCF yield, % | ? | -1.07% | -0.75% | 0.00% | -1.92% | -2.27% | -0.07% | |||
| ROE, % | ? | -11.7% | 10.4% | -10.2% | -10.2% | -6.53% | -8.37% | |||
| ROA, % | ? | -6.74% | 8.16% | -7.94% | -7.94% | -4.96% | -6.33% | |||
| P/E | ? | -48.7 | 62.4 | -40.2 | -43.7 | -54.3 | -40.5 | |||
| P/FCF | -93.3 | -133.2 | -52.0 | -44.1 | -1 367 | |||||
| P/S | ? | 11.4 | 11.4 | 5.66 | 6.14 | 4.14 | 3.53 | |||
| P/BV | ? | 47.5 | 15.2 | 4.09 | 11.1 | 9.87 | 9.18 | |||
| EV/EBITDA | ? | -64.7 | -83.8 | -39.3 | -67.0 | -196.1 | -117.8 | |||
| Debt/EBITDA | 5.06 | 1.18 | 1.13 | 1.76 | 7.74 | 4.11 | ||||
| R&D/CAPEX, % | 819.0% | 497.3% | 339.7% | 176.0% | 703.4% | |||||
| CAPEX/Revenue, % | 2.55% | 3.56% | 0.00% | 5.11% | 10.5% | 2.58% | ||||
| AtriCure shareholders | ||||||||||
